Launch excellence in a disrupted world – challenges & opportunities
A unique example of partnership working across the health system, focusses on the service at large, not just the pill, and uses leading-edge data analytics to analyse, benchmark and visualise the current state of the cancer pathways within the Cancer Vanguard Trusts. Furthermore, it encompasses multiple aspects of the service provision ranging from patient outcomes and experiences, the flow of treatment and the usage of medicine in order to inform an evidence-based and patient-centric approach to service redesign and resource optimisation.
Across Europe, a shift towards greater prevention, earlier diagnosis and treatment is needed in order to contain the growing cost of healthcare. This webinar hosted by pharmaphorum with sponsor PHOENIX group looks at how harnessing the data and expertise of pharmacies, and via greater engagement with patients, consumers and shoppers can meet this emerging need.
Is the UK’s NHS saving enough from the new wave of biosimilars?
Significant unmet need still remains in the rare disease market, only around 5% of rare diseases currently have an approved drug treatment. This represents a major opportunity for the pharmaceutical industry. Our webinar will assess the critical factors underpinning success in the rare disease space and provide a view into the future of market access and health technology assessments for orphan medicines – alongside the impact on R&D and clinical trials – in the context of Brexit negotiations.
Pharmacists are highly trained healthcare professionals who have a deep understanding of medicines and daily contact with patients and consumers, putting them in a unique position in terms of being able to maximise the benefits that patients get from their medicines. However, healthcare systems and pharmaceutical companies frequently overlook this potential.
Join us and Phoenix group as we discuss the concept of current launch excellence and the role of patient insights in overcoming the multiple challenges the industry faces.